[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![AponiaAnalytics Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1816152863069925376.png) aponia_analytics [@AponiaAnalytics](/creator/twitter/AponiaAnalytics) on x 4968 followers
Created: 2025-07-18 22:06:47 UTC

🦉 The subcutaneous GLP-1/GIP agonist is now being evaluated beyond type X diabetes. A successful readout could widen its label and shift competitive dynamics in the diabetes treatment landscape. $NVO $LLY $AZN $SNY $GSK $PFE $RHHBY $ZLDPF $VKTX $VANI $HIMS #tirzepatide #GLP1


XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1946330840033530086/c:line.svg)

**Related Topics**
[hims](/topic/hims)
[pfe](/topic/pfe)
[manat](/topic/manat)
[$hims](/topic/$hims)
[$vani](/topic/$vani)
[$zldpf](/topic/$zldpf)
[$rhhby](/topic/$rhhby)
[$gsk](/topic/$gsk)

[Post Link](https://x.com/AponiaAnalytics/status/1946330840033530086)